secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001628280-24-001000
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Bioworks expects to meet 2023 revenue guidance of $250-260M; cash nearly $950M
--------------------------------------------------------------------------------

- Preliminary cell engineering revenue $145-150M, biosecurity up to $110M, total revenue $250-260M.
- New Cell Programs added expected within 80-85 range, meeting prior guidance.
- Biopharma partnerships with Pfizer, Novo Nordisk, Merck, Boehringer Ingelheim; aggregate potential over $1.2B milestones.
- Ended 2023 with nearly $950M cash and cash equivalents; strong balance sheet.
- Full year 2023 financial results to be reported in February 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/0001628280-24-001000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/dna-20240110.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-001000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer